Visiongain Publishes African Horse Sickness Treatment Market Report to 2031

11 March 2021
Pharma

Visiongain has published a new report on African Horse Sickness Treatment Market Report to 2031: Forecasts by Clinical Forms (Pulmonary Form or “Dunkop”, Cardiac Form or “Dikkop”, Mixed Form, and Horse Sickness Fever), By Diagnosis Tests (Laboratory Tests for Viral Antigens, Enzyme-linked Immunosorbent Assays (ELISA), Reverse-transcription PCR assays, Serological Tests, Prevention Treatment, and Vaccines) PLUS COVID-19 Recovery Scenarios.

Global African Horse Sickness Treatment market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on African Horse Sickness Treatment Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the African horse sickness treatment market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

A Rising Cases of African Horse Sickness
The African horse sickness treatment market is expected to attain a significant growth rate due to the increasing incidence of African horse sickness among horses, mules, and donkeys. According to Statistics, in the last 7 months of 2020, there is an estimated 266 cases of African Horse Sickness has been reported. Hence, the demand for African horse sickness treatment is expected to increase on the account of the rising prevalence rate of African horse sickness.

Rising Focus on Immunization Programs
The rising number of non-government and government campaigns to spread consciousness regarding the significance of immunization to prevent life-threatening infections to animals, in turn, is anticipated to boost the global African Horse Sickness Treatment market growth. For instance, there was an epidemic of African horse sickness aka African Plague in Asia and has killed nearly 550 horses, nearly 12 provinces were affected by the outbreak. To eliminate the infection, Thailand's Government launched a national vaccination program, targeting to immunized all horses in 12 provinces across the country.

Furthermore, on 26th June 2019, Researchers at the Biopharming Research Institute (BRU) have developed a novel vaccine to aid to stop the disturbing effects of African Horse Sickness (AHS). The scientist from the BRU is producing it in tobacco plants.

Market Opportunities

Rapidly Increasing Health Care Expenditure
Healthcare spending has increased drastically in the U.S. in the past few decades. As per the Journal of the American Medical Association (JAMA), healthcare expenditure in the U.S. upsurge near a trillion dollars between 1996 and 2015. The association told that healthcare expenditure in the U.S. during 2017 was around $3.5 trillion, i. e, $11,000 per person. These expenditures are projected to be $6 trillion—approximately $17,000 per person by 2027.

Competitive Landscape
Key players operating in the global African Horse Sickness Treatment market are Veterinary Serum, Onderstepoort Biological Products SOC Ltd.and Vaccine Research Institute

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever